Medical Hypotheses
Volume 56, Issue 6 , Pages 702-708 , June 2001

Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection

Received 15 March 2000 ,Accepted 31 May 2000.

References 

    REFERENCES
  1. Sacher G. Longevety, aging and death; an evolutionary perspective. Gerontologist. 1978;18:112–119
  2. Veldhuis JD, Urban RJ, Lizarralde G. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenemia of healthy aging men. J Clin Endocrinol Metab. 1992;75:52–58
  3. Simpson ER, Mahendroo MS, Means GD. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrin Rev. 1994;15:342–355
  4. Van Gaal LF, Wauters MA, Mertens H. Clinical endocrinology of human leptin. Int J Obes. 1999;23:29–36
  5. Eriksson P, Reynisdottir S, Lonnquist F. Adipose secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia. 1998;41:65–71
  6. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  7. Garrison RJ, Wilson PW, Castelli WP. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism. 1980;29:1053–1060
  8. Zumoff B, Strain GW, Miller LK. Plasma free and non-sex-hormone-binding globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929–931
  9. Hotamisligil GS, Shargill NS, Spiegleman BM. Adipose expression of tumor necrosis factor-a: Direct role in obesity-linked insulin resistance. Science. 1993;259:87–91
  10. Arcaro G, Zamboni M, Rossi L. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes. 1999;23:936–942
  11. Jakab RL, Horvath TL, Leranth C. Aromatase-immunoreactivity in the rat brain: sex hormone-sensitive hypothalamic neurons and a nonresponsive “limbic ring” of the lateral septum-bed nucleus-amygdala complex. J Steroid Biochem Mol Biol. 1993;44:481–498
  12. Borkan GA, Norris AH. Fat redistribution and changing body dimentions of the adult male. Hum Biol. 1977;49:495–514
  13. Hemsell DL, Grodin IM, Brenner PF. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenidione to estrone with age. J Clin Endocrinol Metab. 1974;38:476–479
  14. Schneider G, Kirschner A, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab. 1979;48:633–638
  15. Belanger A, Candas B, Dupont A. Changes in serum concentrations of congutated and uncongugated steroids in 40-to 80-year-old men. J Clin Endocrinol Metab. 1994;79:1086–2010
  16. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt – a major factor in the genesis of morbid obesity. Med Hypoth. 1999;52:49–51
  17. Cohen PG. The role of estradiol in the maintenance of secondary hypogonadism in males with erectile dysfunction. Med Hypoth. 1998;50:331–333
  18. Simon D, Charles MA, Nahoul K. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997;82:682–685
  19. Phillips GB. Evidence for hyperestrogenemia as the link between diabetes mellitus and myocardial infarction. Amer J Med. 1984;76:1041–1048
  20. Phillips GB, Jing TY, Laragh JH, Sealy JE. Serum sex hormone levels and renin sodium profile in men with hypertension. Am J Hypertens. 1995;8:699–702
  21. Phillips GB. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism. 1993;42:116–120
  22. Stevens J, Cai J, Pamuk ER, Williamson DF. The effect of age on the association between body-mass index and mortality. N Eng J Med. 1998;338:1–6
  23. Klein S, Coppack SW, Mohamed-Ali V, Landt M. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes. 1996;45:984–987
  24. Schwartz M, Seeeley RJ, Campfield LA. Identification of targets of leptin action in rat hypothalamus. J Clin Invest. 1996;98:1101–1106
  25. Behre HM, Simoni M, Nieschlag E. Strong association between serum levels of leptin and testosterone in men. Clin Endocrinol. 1997;47:237–240
  26. Vague J. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Amer J Clin Nutr. 1956;4:P20–34
  27. Bjorntorp P. “Portal” adipose tissue as the generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10:117–1124
  28. Rosesell R, Gomis R, Casamitjana R. Reduced hepatic insulin extraction in obesity: relationship with plasma insulin levels. J Clin Endocrinol Metab. 1983;56:608–611
  29. Peiris AN, G. A, M. F. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest. 1986;78:1648–1657
  30. Marin P, Oden B, Bjorntorp P. Assimilation and metabolism of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80:239–243
  31. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest. 1993;92:91–98
  32. Saloranta C, Franssila-Kallunki A, Ekstrand A. Modulation of hepatic glucose production by non-esterified fatty acids in type (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34:409–415
  33. Rebuffe-Scrive M, Anderson B, Olbe L, Bjorntorp P. Metabolism of adipose tissue in intra-abdominal depots of non obese men and women. Metabolism. 1989;38:453–458
  34. Jensen MD, Haymond MW, Rizza RA. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 1989;83:1168–1173
  35. Bjorntorp P, Bergman H, Varnauskas E. Lipid metabolism in relation to body composition in man. Metabolism. 1969;18:840–851
  36. Roden M, Price TB, Perseghin G. Mechanism of free fatty acid-induced resistance in humans. J Clin Invest. 1996;97:2859–2865
  37. Svedberg J, Stromblad G, Wirth A. Fatty acids in the portal vein of the rat regulate hepatic insulin clearance. J Clin Invest. 1991;;88:2054–2058
  38. Pouliot MC, Despres JP, Nadeau A. Visceral obesity in men. Associations with glucose intolerance, plasma insulin and lipoprotein levels. Diabetes. 1992;41:826–834
  39. Reaven GM, Chen YDI, Jeppesin J. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 1993;92:141–146
  40. Despres JP, Lemieux S, Lamarche B. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Intern J Obes. 1995;19:576–586
  41. Modan M, Halkin H, Almog S, Lusky A, Eshkol A. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985;75:809–817
  42. Reaven GM. Role of insulin resistance in human disease (Syndrome X): An expanded definition. Ann Rev Med. 1993;44:121–131
  43. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. Circulation. 1988;78:539–545
  44. Haffner SM, Mykkanen L, Valdez RA, Katz MS. Relation of sex hormones to lipids and lipoproteins in non-diabetic men. J Clin Endocrinol Metab. 1993;77:1610–1615
  45. Anderson RA, Wallace EM, Wu FC. Effect of testosterone enanthate on serum lipoproteins in man. Contraception. 1995;52:115–119
  46. Handlesman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA. Establishing the minimum effective dose and additive effects of depot progestin on suppression of human spermatogenesis by testosterone depot. J Clin Endocrinol Metab. 1996;81:4113–4121
  47. Tan KCB, Shiu SWM, Pang RWC, Kung AWC. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrin. 1998;48:187–194
  48. Crook D, Seed M. Endocrine control of lipoprotein metabolism: effects of gonadal steroids. Balliere’s Clinical Endocrinol Metab. 1990;4:851–876
  49. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104–109
  50. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor I and atherothrombosis. Thromb Haemost. 1993;70:138–143
  51. Caron P, Benet A, Camare R, Louvet JP. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism. 1988;38:1010–1015
  52. Glueck CJ, Glueck HI, Stroop D, Spiers J, Hamer T, Tracy T. Endogenous testosterone fibrinolysis, and coronary heart disease risk in hyperlipideamic men. J Lab Clin Med. 1993;122:412–420
  53. Stephansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha, beta binding to vitronecton. Nature. 1996;383:441–443
  54. Assmann G, Schulte H, Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-age men. Am J Cardiol. 1996;77:1179–1184
  55. Zmuda JM, Thompson PD, Dickerson R, Bausserman LL. Testosterone decreases lipoprotein (a) in men. Amer J Cardiol. 1996;1244–1247
  56. Biring MS, Lewis MI, Liu JT, Mohsenifar Z. Pulmonary physiologic changes of morbid obesity. Am J Med Sci. 1999;318:293–297
  57. Strollo PJ, Rogers RM. Obstructive sleep apnea. N Eng J Med. 1996;334:99–104
  58. Ball EM, Simon RD, Tall A. Diagnosis and treatment of sleep apnea within the community. Arch Intern Med. 1997;157:419–424
  59. Strohl KP. The biology of sleep apnea. Science Med. 1996;3:32–41
  60. Hirshkowitz M, Karacan I, Arcasoy MO. Prevalence of sleep apnea in men with erectile dysfunction. Urol. 1990;36:232–234
  61. Harris T. Muscle mass and strength: relation to function in population studies. J Nutr. 1997;127:1004S–1006S
  62. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127:9905–9915
  63. Holloszy JO. Workshop on sarcopenia: muscle atrophy in old age. J Gerontol. 1995;50A:1–161
  64. Francis RM, Peacock M, Aaron PL. Osteoporosis in hypogonadal men: Role of decreased plasma 1,25-Dihydroxy D, calcium malabsorption and low bone formation. Bone. 1986;7:261–268
  65. Snyder PJ, Peachey H, Hannoush P. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrin Metab. 1999;84:1966–1972
  66. Rudman D, Feller AG, Cohn L, Shetty KR, Rudman IW, Draper MW. Effects of human growth hormone on body composition in elderly men. Horm Res. 1991;36:73–81
  67. Cohen PG. The association of premature ejaculation and hypogonadotropic hypogonadism. J Sex Marital Ther. 1997;;

PII: S0306-9877(00)91169-1

doi: 10.1054/mehy.2000.1169

Medical Hypotheses
Volume 56, Issue 6 , Pages 702-708 , June 2001

Article Tools